AstraZeneca announces Phase 3 data for new crown vaccine

On March 25, local time, AstraZeneca's official website announced that the preliminary analysis results of the phase III clinical trial of the new crown vaccine AZD1222 were consistent with the interim analysis results announced on March 22.

The new crown vaccine AZD1222 was jointly invented by the University of Oxford and Vaccitech.

It uses a replication-deficient chimpanzee virus vector based on a weakened version of the common cold adenovirus, which causes infection in chimpanzees and contains the genetic material of the spike protein of the SARS-CoV-2 virus.

After vaccination, a surface spike protein is produced, which stimulates the immune system to attack the SARS-CoV-2 virus.

The main efficacy analysis of the phase III clinical trial of AZD1222 included a total of 190 COVID-19 patients, an increase of 49 cases from the interim analysis, of which 14 cases may need to be adjudicated, so the total number of cases may fluctuate slightly.

Clinical results show that the vaccine has an efficacy of 76% (CI: 68%-82%) in preventing symptomatic COVID-19; in addition, the results of all age groups are similar, and the efficacy of the vaccine for adults 65 years and older is 85% (CI : 58%-95%); the key secondary endpoints for the prevention of severe or critical illness and hospitalization confirmed 100% efficacy; these data further prove that the AstraZeneca vaccine is safe and effective.

This is the latest official data released after the safety of AZD1222 has been questioned by the US Data Security Monitoring Board (DSMB).
It is reported that the Phase III clinical results of AZD1222 have been submitted to the independent Data Security Monitoring Board (DSMB).

The main analysis has been pre-prescribed in the trial protocol and will be the regulatory basis for submitting an emergency use authorization (EUA) to the US FDA in the next few weeks.

AstraZeneca said that the main analysis results of AZD1222 will be submitted in the next few weeks for peer review publication.

So far, the cumulative number of confirmed diagnoses in the world has exceeded 100 million.
It is hoped that the new crown vaccine can help end the epidemic as soon as possible and end this nightmare.

End reference materials: [1] .
html[2]https://med.
sina.
com/article_detail_103_2_97963.
html Selected in the past to watch EBC 2021 | Interview with Ren Xueyun, head of Sartorius AS: Create a complete solution and be a trusted biopharmaceutical partner Studies have found that: artificial sweeteners can promote the development of systemic inflammation and fatty liver, but there is one kind of sweetener except that the heat is overweight and the health is the survivor's deviation? New research reveals that some genes can increase the risk of obesity, but can also prevent cardiovascular and metabolic diseases! If you want to do well, you must sharpen your tools first! New single-cell technology reveals a new mechanism for immune checkpoint regulation Hot article 3.
21 World Down's Syndrome Day | May every life be tendered by the world for medical immunotherapy | Biosimilars | Vaccines | Drug resistance | Drug targets | Healthy Life| Pharmaceutical News| Drug Inventory| Pharmaceutical Technology| Fundamental Research on Drug Side Effects/Translational Medicine Leukemia| Lung Cancer| Gastric Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Disease| Intestinal Microbe Medical Devices/Biotechnology In Vitro Diagnostics | Medical Devices | Bio Nanos | 3D Printing | Genetic Testing | Single Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision Medicine Policy Anti-cancer Drugs | 4+7 Volume Procurement | Consumables | Filing System | Registrant System | Healthy China | New Edition of Essential Medicine Catalog | AI Medical Devices | Telemedicine | Same Equity Different Equity Market/Capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | ChiNext | R & D Investment | Acquisition | Market & Consumption